Iovance Biotherapeutics Inc
$ 3.78
30.80%
24 Feb - close price
- Market Cap 1,500,539,000 USD
- Current Price $ 3.78
- High / Low $ 3.90 / 3.21
- Stock P/E N/A
- Book Value 1.70
- EPS -1.19
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.27 %
- ROE -0.56 %
- 52 Week High 5.64
- 52 Week Low 1.64
About
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company is headquartered in San Carlos, California.
Analyst Target Price
$9.22
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-12-31 | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-02-26 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-28 | 2023-11-07 | 2023-08-08 | 2023-05-09 |
| Reported EPS | -0.18 | -0.25 | -0.33 | -0.36 | -0.26 | -0.28 | -0.34 | -0.42 | -0.45 | -0.46 | -0.47 | -0.5 |
| Estimated EPS | -0.1764 | -0.2617 | -0.28 | -0.42 | -0.2676 | -0.3 | -0.35 | -0.42 | -0.43 | -0.45 | -0.8 | -0.74 |
| Surprise | -0.0036 | 0.0117 | -0.05 | 0.06 | 0.0076 | 0.02 | 0.01 | 0 | -0.02 | -0.01 | 0.33 | 0.24 |
| Surprise Percentage | -2.0408% | 4.4708% | -17.8571% | 14.2857% | 2.8401% | 6.6667% | 2.8571% | 0% | -4.6512% | -2.2222% | 41.25% | 32.4324% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IOVA
2026-02-24 16:52:57
Iovance Biotherapeutics (IOVA) surged approximately 26% following its Q4 2025 financial results, which exceeded revenue expectations. The company also announced promising data from a clinical trial for its one-time therapy, Amtagvi (lifileucel), in treating soft tissue sarcomas.
2026-02-24 14:52:57
Iovance Biotherapeutics, Inc. has released its 2025 Form 10-K report, detailing a 61% increase in total product revenue to $263.5 million, driven by Amtagvi® sales, despite an increased net loss and continued cash usage in operating activities. The report highlights the company's focus on TIL cell therapies for solid tumor cancers, expansion of Amtagvi®'s market, and strategic initiatives to improve manufacturing and optimize costs. Significant operational, financial, regulatory, and market risks are also acknowledged, alongside strategies to manage these challenges and extend cash runway.
2026-02-24 14:52:57
Iovance Biotherapeutics (IOVA) stock surged over 20% due to promising real-world data for its advanced melanoma treatment, Amtagvi, and an increased price target from Goldman Sachs. Despite considerable revenue, the company faces profitability challenges with significant net losses and negative margins. The stock's rise is further supported by strategic workforce expansion and FDA backing for Amtagvi, signaling potential long-term growth in the cancer therapeutics market.
2026-02-23 17:23:47
Iovance Biotherapeutics (IOVA) has shared new data for its commercial therapy Amtagvi, showcasing a best-in-class profile with unprecedented response rates in advanced melanoma patients. This data, presented at the 2026 Tandem Meetings, has prompted analysts like H.C. Wainwright and Barclays to reiterate positive ratings and price targets for the stock. Amtagvi is noted as the first one-time T cell therapy for a solid tumor cancer and the only FDA-approved treatment for specific advanced melanoma cases.
2026-02-23 14:50:04
Iovance Biotherapeutics (IOVA) announced new data for its commercial therapy, Amtagvi (lifileucel), showing unprecedented response rates in advanced melanoma patients. This led H.C. Wainwright and Barclays to reiterate their Buy and Overweight ratings, respectively, with price targets of $9 and $10. Amtagvi is noted as the first one-time T cell therapy for solid tumor cancer and the only FDA-approved treatment for specific advanced melanoma cases.
2026-02-23 14:50:04
Iovance Biotherapeutics Inc. is set to release its Q4 and full-year 2025 results, with analysts anticipating a loss of 17 cents per share on $82.03 million in revenue, suggesting significant sequential improvement and accelerating adoption of its cancer therapy, Amtagvi. The company's real-world data for Amtagvi has shown promising results in advanced melanoma, potentially boosting physician confidence and uptake. Investors will closely monitor whether strong clinical data translates into sustained revenue growth, improved gross margins from the current 21%, and progress toward profitability, especially given the company's past challenges in meeting revenue forecasts despite narrowing losses.
